- Myrtle Potter, former President and COO of Genentech, appointed Vant Operating Chair
- RVT-1401, novel anti-FcRn antibody, to serve as lead asset for Immunovant
- Additional milestones announced across the public and private Vants
BASEL, Switzerland and NEW YORK, July 10, 2018 /PRNewswire/ — Roivant Sciences announced a series of corporate updates across the Roivant family of companies in advance of its first annual Pipeline Day this afternoon in New York City.
Enzyvant announced the initiation of a rolling BLA submission for RVT-802 for the treatment of complete DiGeorge Anomaly.
Genevant announced a significant strategic partnership with BioNTech, advancing 5 mRNA-based therapeutic candidates into development.
Axovant announced the expansion of its gene therapy pipeline with the addition of AXO-AAV-OPMD for the treatment of oculopharyngeal muscular dystrophy.
Myovant announced the close of screening in the Phase 3 LIBERTY 1 study for relugolix in uterine fibroids with data expected in Q2 2019.
Arbutus announced the first patient has been dosed in a clinical trial for AB-506, Arbutus’ second-generation capsid inhibitor, and the advancement of AB-452, Arbutus’ novel RNA destabilizer, into clinical trials later this quarter, paving the way for all-oral combination studies in hepatitis B patients in 2019.
Urovant announced the appointments of Sef Kurstjens and Pierre Legault to its board of directors.
Roivant announced that RVT-1401 (previously HL161) will form the foundation of a new company, Immunovant. RVT-1401 is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). Blockade of FcRn-Immunoglobulin G (IgG) interactions has been shown to lead to the rapid depletion of IgG. RVT-1401 has potential as a treatment for IgG-mediated autoimmune diseases. Preliminary clinical data from an ongoing Phase 1 study for RVT-1401 will be presented later today at Pipeline Day.
Appointment of Myrtle Potter as Vant Operating Chair
Roivant also announced that Myrtle Potter will be joining the company as Vant Operating Chair. In this role, she is expected to serve as one of two Roivant representatives on the boards of all biopharmaceutical companies in the Roivant family.
“We are excited to welcome Myrtle to Roivant, in a role where she will be well positioned to support our CEOs and ensure operational excellence across our family of companies,” said Mayukh Sukhatme, MD, President of Roivant Pharma.
“I am excited to play an important role in the growth and development of companies across the Roivant family,” said Ms. Potter. “It is my belief that the Roivant model represents the future of industrial organization in the biopharmaceutical industry, and I look forward to drawing on my operating experience at companies like Genentech and my board experience at companies like Amazon to help lead Roivant towards a dominant position in biopharma.”
Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year. Prior to Genentech she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Rite Aid and Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.
About Roivant Pipeline Day
Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City. The event will feature presentations, fireside chats, and Q&A sessions from executives across the Roivant family of companies. The event is scheduled to begin at 2:00 p.m. ET and will continue until approximately 5:30 p.m. ET. Due to limited capacity, attendance is by invitation only but a live webcast will be available to interested parties. To request access to the webcast or to learn more about the event, please email email@example.com.
Roivant Sciences is a global biopharmaceutical company focused on reducing the time and cost of the drug development process to improve the lives of patients and their families. Roivant partners with innovative companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients upon approval.
The Roivant family of companies includes Myovant (women’s health), Axovant (neurology), Urovant (urology), Enzyvant (rare diseases), Dermavant (dermatology), Genevant (RNA therapeutics), Metavant (cardiometabolic diseases), Altavant (next-generation drug development), Immunovant (immunology), Datavant (healthcare data), and Arbutus (hepatitis B).
Today there are 30 investigational drugs in 11 therapeutic areas being tested in over 50 clinical trials across the Roivant family of companies.
For more information, please visit www.roivant.com.